Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast Foam 0.3% in Seborrheic Dermatitis
NCT07683806Phase 3Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of roflumilast vehicle cream in seborrheic dermatitis (SD) (2 arms), sponsored by Huadong Medicine. Primary endpoint: Investigator Global Assessment success at 8 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
roflumilast vehicle cream
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT07683806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683806.